Outlook Therapeutics, Inc. (OTLK) stock
Close on Nov 13, 2026Market cap $100.54MP/E –Yield –
Outlook Therapeutics, Inc. reported revenue of $1.41M for fiscal 2025. At the latest close the market valued the company at $100.54M.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $100.54M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $1.41M
- Net income
- -$61.12M
- EPS, diluted
- -$0.86
- Book value per share
- -$0.08
- Diluted shares
- 137M
Trading
- Next earnings
- Dec 18, 2026 (estimated, before the open)
- Previous close
- $0.44
- Open
- $0.46
- Day's range
- $0.41 – $0.46
- Volume
- 3,025,431
- Average volume (20 days)
- 3,017,909
- Beta (5 years)
- 0.97
- 52-week range
- $0.16 – $2.54
- RSI (14 days)
- 33.5
- Volatility (1 year)
- 152.3%
- Relative volume
- 0.29×
- WACC
- 10.0%
Market cap history
Month-end market cap since 2016, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | OTLK | S&P 500 | Difference | OTLK per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -26.7% | -3.0% | −23.7 pts | ||
| 3 months | -53.5% | -2.8% | −50.8 pts | ||
| Year to date | -73.9% | +11.5% | −85.3 pts | ||
| 1 year | -71.9% | +13.5% | −85.4 pts | ||
| 3 years | -94.9% | +77.7% | −172.6 pts | -62.9% | +21.1% |
| 5 years | -99.0% | +72.6% | −171.6 pts | -60.1% | +11.5% |
| 10 years | -99.9% | +308.2% | −408.1 pts | -51.9% | +15.1% |
Twelve years at a glance
Fiscal years 2014 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Outlook Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- News
- News
- News
- News
About Outlook Therapeutics
Biological Products, (No Diagnostic Substances)
The company is a biopharmaceutical business focused on developing and commercializing ophthalmic treatments for retinal conditions. Its lead product is ONS-5010/LYTENAVA, an ophthalmic formulation of bevacizumab designed to treat wet age-related macular degeneration in adults as an alternative to off-label compounded bevacizumab. It also explores indications for diabetic macular edema and branch retinal vein occlusion, alongside maintaining rights to legacy biosimilar candidates. The company targets the global retina care community, serving patients, payors, and ophthalmologists or retina specialists.
Company profile, executives and historyOutlook Therapeutics stock: common questions
What is Outlook Therapeutics's stock price?
OTLK closed at $0.41 on Nov 13, 2026, down 6.16% on the day. Over the past 52 weeks it traded between $0.16 and $2.54.
What is Outlook Therapeutics's market cap?
Outlook Therapeutics was worth $100.54M at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
What is OTLK's P/E ratio?
Outlook Therapeutics lost money over the twelve months to Jun 30, 2026 (diluted EPS -$0.86), so it has no meaningful P/E ratio.
How much revenue does Outlook Therapeutics make?
Outlook Therapeutics reported revenue of $1.41M for fiscal 2025.
Does Outlook Therapeutics pay a dividend?
No. Outlook Therapeutics has not paid a cash dividend over the last twelve months.
When does Outlook Therapeutics report earnings next?
Outlook Therapeutics is expected to report Q4 FY2026 results on Dec 18, 2026, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has OTLK stock performed over the past year?
Including dividends, OTLK returned -71.9% over the past year, against +13.5% for the S&P 500.
How many OTLK shares are sold short?
36M shares were sold short at the latest FINRA report, 20.41% of the float, or 10.1 days of average trading volume.
Who are Outlook Therapeutics's competitors?
Companies most similar to Outlook Therapeutics by business, industry and size include SCNI, SRRK, INBX, OCGN, CMPX.
See a number that looks wrong?